Microbot Medical (Nasdaq:MBOT) announced today that it began the U.S. commercial launch of its Liberty endovascular surgical robot.
In September, Liberty became the first FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures. Microbot says its system aims to advance robotics without the constraints of capital equipment and a dedicated infrastructure.
Hingham, Massachusetts-based Microbot designed the Liberty robot to democratize endovascular interventional procedures. The company says it’s the world’s first single-use, fully disposable robotic system for those procedures.
Since clearance, Microbot has boosted its commercialization efforts with significant funding. The company exercised certain investment options worth up to $92.2 million last month to support the Liberty rollout. It also partnered with a third-party logistics company to support its Liberty launch the following week.
Now, the company says it kicked off the limited rollout for the surgical robot system. Microbot plans for the limited market release to introduce Liberty to select high-volume regions where it already saw preliminary demand. The company aims to collect real-world insights from potential high-volume users to guide responsible growth and ensure consistent quality and performance.
Microbot plans to use its preliminary launch to inform its full market release. The company expects to fully launch Liberty during the Society of Interventional Radiology (SIR) conference in April 2026.
“We are excited to enter the commercialization phase of Liberty. We are building a new robotic category with the introduction of Liberty, the world’s first single-use robotic system. Launching just weeks after announcing FDA clearance, we believe that we have demonstrated the strength of our team and the unique innovation behind Liberty,” commented Harel Gadot, CEO, president and chair. “Building on the strong interest and feedback we have received so far from physicians and hospital administrators, the limited market release is expected to enable us to responsibly support early adopters and lay the groundwork for a full market launch at the Society of Interventional Radiology meeting in April.”
